Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Phase II Trial of Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer

NCT06462053 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06462053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06462053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Phase II Trial of Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
April 1, 2024
Completion date
March 1, 2027
Enrollment
134 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

early low rectal cancer